Researchers discover a possible treatment that can treat genetic blindness

Researchers from the American University of Western Reserve make it possible to discover two new compounds that could possibly treat the inflammation of the chest, a group of genetic diseases that lead to gradual loss of vision. The genetic mutations that disrupt proteins cause a group of diseases known as protein formation that affect membrane proteins, including protein receptors that are especially Renaissance for wrong fold. Patients with gravity retinitis suffer from genetic mutations that lead to an abnormal fold of “Rhodopsin” protein in the retina, which gradually causes retinal cells and visual loss. There is a “rhodopine”, which is a membrane protein, in the sticks in the retina, and is essential in the vision process, where it responds to light and helps to convert the optical signals into nerves signals sent to the brain. The genetic mutations in the “Rhodopsin” gene can lead to protein fold in the cells, which effectively impedes the transmission of light and leads to vision problems. Diseases related to Rhodopsin mutations and the most prominent diseases associated with the mutations of Rhodopsin are the ‘genetic degeneration associated with genetics’, or ‘degeneration of gravitational network’, which is considered one of the most prominent causes of genetic blindness. In this case, the mutations in the gene lead to the formation of deformed or unstable Rhodopsin proteins, leading to the accumulation of proper proteins in the retina and the decline of the Bacilli cells, which in turn leads to a decline in the capacity of night vision and then the loss of Peripheral vision can develop, and developed. The relationship between Rhodopsin and the disease is that genetic mutations in rhodopinine protein mainly contribute to the mechanism of the disease through its impact on cells’ ability to treat light, which increases the understanding of the mechanism that leads to related diseases, and to develop possible treatment strategies to improve or improve the effectiveness of distorted protein. While the current experimental treatments depend on the “retinoids”, such as artificial vitamin A derivatives, which are allergic to light and toxic side effects, which limit its effectiveness. Current experimental treatments are based on a group of substances known as ‘retinoids’ to improve the fold of membrane proteins such as Rhodopsin, but they suffer from various problems that limit their therapeutic effectiveness. These problems include sensitivity to light as their chemical formula deteriorates when exposed to light, chemical interaction with other molecules, which can lead to harmful or ineffective interactive products. It also suffers from poor chemical stability, making its use as a long -term treatment difficult; Due to the rapid dissolution in the body, it requires repetition of doses or developing more stable compounds. Some retinoids cause side effects such as skin irritation, dryness and excessive sensitivity to light, which require accurate monitoring when used, so there is a need not to develop alternative compounds characterized by more effective and stability, while reducing chemical reaction and side effects, to effectively use safe and effective use in different treatments. A hypothetical examination in the study published in the “Plos Biology” journal used the researchers the virtual investigation to look for new pharmaceutical molecules that can be associated with rhodopin protein and the stabilization of the structure to improve the fold and movement within the cell. Not -otinophidic compounds have been identified with the ability to cross the circulatory barrier and retinal barrier. Laboratory experiments showed that these compounds improved the expression of Rhodopsin on the surface of the cell in 36 out of 123 genetic species of gravity rhetinal inflammation, including the most common type. The vehicles also helped dissolve the retinal cells against the mice with the disease. The researchers pointed out that the treatment of one of the vehicle summarized the health and function of the retina in general in mice as it led to the extension of the age cells of the light receptors. However, they emphasized the need for more studies on these compounds or similar connections before testing treatments on people. The study confirmed that the genetic mutations in the Rhodopsin were the cause of pigment inflammation, which is a gradual disease that leads to visual loss and has no current treatment. This research is a step towards presenting a new therapeutic approach aimed at preventing visual loss in patients.